Business Description
ImmuCell Corp
NAICS : 325412
SIC : 2834
ISIN : US4525253062
Description
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.06 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.66 | |||||
Debt-to-EBITDA | -25.75 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.11 | |||||
Beneish M-Score | -2.63 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 2 | |||||
3-Year EPS without NRI Growth Rate | -44.7 | |||||
3-Year FCF Growth Rate | -30.5 | |||||
3-Year Book Growth Rate | -6.3 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 38.44 | |||||
9-Day RSI | 41.29 | |||||
14-Day RSI | 42.51 | |||||
6-1 Month Momentum % | -12.22 | |||||
12-1 Month Momentum % | -14.54 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.71 | |||||
Quick Ratio | 1 | |||||
Cash Ratio | 0.23 | |||||
Days Inventory | 171.43 | |||||
Days Sales Outstanding | 35.2 | |||||
Days Payable | 19.5 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | -10.97 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 27.55 | |||||
Operating Margin % | -17.81 | |||||
Net Margin % | -18.31 | |||||
FCF Margin % | -13.06 | |||||
ROE % | -14.92 | |||||
ROA % | -8.92 | |||||
ROIC % | -9.48 | |||||
ROC (Joel Greenblatt) % | -8.45 | |||||
ROCE % | -8.45 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.54 | |||||
PB Ratio | 1.33 | |||||
Price-to-Tangible-Book | 1.34 | |||||
EV-to-EBIT | -14.41 | |||||
EV-to-EBITDA | -76.64 | |||||
EV-to-Revenue | 2.28 | |||||
EV-to-FCF | -17.47 | |||||
Price-to-Median-PS-Value | 0.57 | |||||
Earnings Yield (Greenblatt) % | -6.94 | |||||
FCF Yield % | -8.37 | |||||
Forward Rate of Return (Yacktman) % | 11.53 |